Across 8 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Becton, Dickinson and Company news is Somewhat Bullish (+44)
on a scale from −100 to +100.
That is up 13 points from the previous 30 days (+31).
Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. Sells ...
AI-generated analysis
Key insights
📈 Becton, Dickinson and Company reported quarterly revenue of $5.27 billion, beating analyst estimates of $5.11 billion by $160 million.
💰 The company posted earnings per share of $4.15, topping the consensus estimate of $4.07 by $0.08.
🔄 BDX authorized a new share repurchase plan allowing the buyback of up to 10 million shares or 3.6% of outstanding equity.
💵 The company declared a quarterly dividend of $1.06 per share, an increase from the previous quarter's $1.05 payout.
📉 CEO Thomas Polen Jr. sold 2,993 shares for $628,530 under a pre-arranged Rule 10b5-1 trading plan, reducing his stake by 2.65%.
🏦 BlackRock Inc. increased its position in BDX by approximately $3.7 billion during the second quarter.
📈 State Street Corp boosted its holdings by 8.5%, adding over 1.1 million shares to its portfolio.
🔍 Zacks Research upgraded BDX from a 'hold' rating to a 'strong-buy' rating in late October.
🎯 The consensus analyst target price for BDX is $195.47, with Jefferies Financial Group setting a high target of $242.
📈 Bullish signals
📈Revenue grew 5.4% year-over-year to $5.27 billion, exceeding analyst consensus estimates of $5.11 billion.
💰Earnings per share reached $4.15, beating the expected $4.07 by $0.08, demonstrating strong operational execution.
🔄The company authorized a new share repurchase program for up to 10 million shares, signaling management confidence in the stock's valuation.
💵Becton, Dickinson and Company increased its quarterly dividend to $1.06 per share from the previous $1.05.
🏦Major institutional investors including BlackRock, State Street, and First Eagle significantly increased their holdings in the second quarter.
🔍Zacks Research upgraded the stock to a 'strong-buy' rating following the strong quarterly earnings beat.
📉 Risk factors
📉The CEO sold 2,993 shares worth $628,530, representing a 2.65% reduction in his personal stake, though executed under a pre-arranged trading plan.
📉Barclays initiated coverage with an 'underweight' rating and set a price objective of $165, which is below the current market price.
Article
Becton, Dickinson and Company (NYSE:BDX) reported strong quarterly financial results for the period ending in late October, with revenue reaching $5.27 billion, a 5.4% year-over-year increase that beat analyst consensus estimates of $5.11 billion. The company posted earnings per share of $4.15, surpassing the expected $4.07, while maintaining a net margin of 4.52% and a return on equity of 14.79%. This performance highlights the medical instruments supplier's ability to grow revenue and profitability in its core healthcare markets.
Following the earnings release, the company announced a new share repurchase plan authorizing the buyback of up to 10 million shares, representing approximately 3.6% of its outstanding equity. Additionally, BDX declared a quarterly dividend of $1.06 per share, payable on December 31st to shareholders of record by December 10th. This marks an increase from the previous quarterly dividend of $1.05, reflecting a commitment to returning capital to investors despite a payout ratio exceeding 100%.
Institutional investor sentiment remains robust, with major funds like BlackRock, State Street, and First Eagle increasing their stakes in the second quarter. Analyst consensus is moderately bullish, with an average target price of $195.47 and recent upgrades from Zacks Research to a 'strong-buy' rating. While CEO Thomas Polen Jr. sold shares under a pre-arranged plan, the broader market data suggests confidence in BDX's long-term trajectory.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Becton Dickinson (BDX) shares are trading in the mid-$140 range on the NYSE, reflecting a roughly 49% decline from their July 2023 peak of $287.32. This muted performance over the last three years contrasts with the broader S&P 500 index, prompting renewed analyst attention regarding the company's valuation and future prospects.
Bank of America recently trimmed its price target for Becton Dickinson in mid-June 2026, citing ongoing headwinds within the medical technology sector and a less favorable risk-reward profile for specific procedure-dependent product lines. Despite this caution, the bank maintains its view of BD as a core large-cap name with a diversified portfolio spanning diagnostics, medical devices, and interventional products.
Consensus data from MarketScreener indicates that a solid majority of analysts still rate Becton Dickinson as Buy or Outperform, with average 12-month price targets sitting noticeably above the current share price. However, several brokers have adopted more cautious language regarding hospital capital budgets and procedure volumes, which could weigh on near-term growth.
The company generates revenue across three main segments: BD Medical, BD Life Sciences, and BD Interventional, supplying hospitals and clinicians globally with devices for medication management and diagnostics. Investors are currently tracking the next earnings date to determine if the stock can recover from its significant discount to all-time highs amidst normalized procedure growth.
📉 Shares trade at $145.43, down 49% from July 2023 high.
🏦 Bank of America lowered target due to medtech headwinds in June 2026.
📊 Majority analysts maintain Buy ratings with targets above current price.
⚠️ Brokers warn on hospital budgets and procedure volume impacts.
💼 Company spans Medical, Life Sciences, and Interventional segments globally.
📉 Becton Dickinson shares trade around $145.43, representing a roughly 49% decline from the July 2023 all-time high of $287.32.
🏦 Bank of America trimmed its price target in mid-June 2026 due to medtech headwinds and unfavorable risk-reward profiles for procedure-dependent lines.
📊 Consensus data shows a majority of analysts still rate Becton Dickinson as Buy or Outperform with targets above current levels.
⚠️ Several brokers have adopted cautious wording regarding hospital capital budgets and procedure volumes affecting near-term growth.
💼 The company operates across three segments: BD Medical, BD Life Sciences, and BD Interventional serving global healthcare needs.
📈 Investors are closely monitoring the next earnings date to assess potential recovery from the muted three-year performance.
🌍 European trading platforms show shares quoted around 123 euros, reflecting the same underlying valuation trends as U.S. markets.
Bullish Signals
Majority of analysts rate Becton Dickinson Buy or Outperform.
Average 12-month price target sits above current share price.
Bank of America views BD as core large-cap med tech.
Risk Factors
Muted three-year performance versus S&P 500 index.
Ongoing medtech headwinds and unfavorable risk-reward profile.
Cautious outlook on hospital capital budgets and volumes.
Bullish Signals
A solid majority of covering houses still rate Becton Dickinson at Buy or Outperform according to consensus data.
The average 12-month price target sits noticeably above the current share price, pointing to perceived upside from current levels.
Bank of America continues to view BD as a core name within large-cap medical technology despite recent target cuts.
Risk Factors
Becton Dickinson shares have experienced a muted three-year performance versus the wider S&P 500 index.
Bank of America cited ongoing medtech headwinds and a less favorable risk-reward profile for some procedure-dependent product lines.
Several brokers have adopted more cautious wording around hospital capital budgets and procedure volumes, which could weigh on near-term growth.
Becton, Dickinson and Company (NYSE:BDX) received strong praise from Jim Cramer on Yahoo Finance's 'Mad Money' following a recent earnings report. Cramer highlighted that the medical supplies and technology giant delivered a significant beat in both top-line revenue and bottom-line profit. He noted that management has raised its full-year earnings forecast, demonstrating excellent execution across the business.
Cramer emphasized that BDX is trading at what he considers the lowest valuation level he has ever seen for the stock. Despite broader market concerns about near-term headwinds from increased AI-related spending, Cramer views BDX as a solid buy-and-hold opportunity. He specifically pointed out that the company benefits from technology helping hospitals operate more efficiently with fewer staff.
The stock surged nearly 6% on the day of the commentary despite a generally poor market environment. While Cramer acknowledged that other AI stocks might offer greater upside potential, he maintained that BDX is very inexpensive and suggested investors buy some shares to wait for any further downside before accumulating more.
📈 Jim Cramer praises BDX for shooting lights out earnings.
💰 Revenue and profit beat prompted full-year forecast raise.
📉 Stock trades at lowest valuation level ever seen.
Jim Cramer expressed a bullish view on Becton, Dickinson and Company (NYSE: BDX) during an appearance on his show, noting that the stock is trading at what he considers its lowest market level in years. He advised investors to purchase shares now and wait for potential further declines, describing the valuation as very inexpensive. Cramer highlighted a recent strong quarterly performance where the company significantly beat earnings expectations on both the top and bottom lines. Following this positive earnings report, management raised their full-year earnings forecast, which contributed to a nearly 6% surge in the stock price despite broader market weakness.
Cramer praised BDX's execution and noted that the company is benefiting from technology advancements that allow hospitals to operate more efficiently with fewer staff members. While acknowledging the investment potential of BDX, he contrasted it with other AI-focused stocks, suggesting that some pure-play AI companies might offer higher returns over a shorter timeframe. He specifically mentioned a hypothetical "cheapest AI stock" with exaggerated upside potential as an alternative for investors seeking greater growth, though this was framed as a promotional comparison rather than a direct critique of BDX's fundamentals. The core takeaway is Cramer's conviction that BDX is undervalued and well-positioned due to its recent operational success and earnings beat.
📉 BDX trades at a historic low valuation despite strong recent earnings beats.
🚀 Management raised full-year forecasts as AI tech boosts hospital efficiency.
⏳ Cramer advises buying now but warns of broader AI spending headwinds.
📉 Jim Cramer notes Becton, Dickinson (BDX) is trading at the lowest valuation level he has ever seen for the stock.
📈 The company recently reported a strong quarter with a significant beat in both top-line and bottom-line earnings.
🚀 Management raised its full-year earnings forecast following the positive results.
🤖 BDX is benefiting from technology that enables hospitals to perform more tasks with fewer staff members.
⏳ Cramer advises investors to buy some shares now and wait to see if the stock oversells further before adding more.
⚠️ He warns that increased AI-related spending could create near-term headwinds for the broader market.
🧠 While acknowledging BDX's investment potential, Cramer suggests other AI stocks may offer higher returns in a shorter timeframe.
📊 The stock rose nearly 6% on the day of the earnings report despite a generally poor market performance.
🏥 Becton, Dickinson sells medical supplies, diagnostic tools, and lab equipment to healthcare professionals and researchers.
📅 This commentary was published on June 6, 2026, following the May 7 earnings episode discussion.
Becton Dickinson (BDX) has resumed shipments of its ChloraPrep antiseptic product in the U.S. following a voluntary hold that began on May 6, 2026. The company placed the shipment on hold to conduct additional final release testing after receiving an FDA Warning Letter regarding its El Paso manufacturing facility. BD reports that all added tests conducted so far have been acceptable and no patient safety signals have been identified, allowing for the resumption of shipments to safeguard continuity of patient care while regulatory concerns are addressed.
While the immediate supply disruption for ChloraPrep has been mitigated, reducing near-term operational risk for customers relying on the product in clinical settings, the underlying FDA Warning Letter for the El Paso plant remains an overhang. Investors and healthcare providers are expected to monitor how BD manages these compliance issues and any broader implications for its manufacturing network and product portfolio.
Analyst sentiment on BDX is currently neutral, with a Hold rating and a $161.00 price target. This assessment is driven by the company's solid financial quality, including strong free cash flow and improving leverage, as well as supportive earnings-call guidance that raised adjusted EPS. However, these positives are tempered by weak technical indicators, such as the stock trading below key moving averages with a negative MACD, and a less helpful valuation signal due to a negative P/E ratio. Additionally, near-term operational headwinds from tariffs, China, and the temporary FDA-related shipment hold continue to influence the outlook.
🏭 BD resumes ChloraPrep shipments after FDA-mandated hold ends with acceptable testing.
⚠️ El Paso plant regulatory issues persist despite shipment resumption and safety clearance.
🏭 Becton Dickinson (BDX) has resumed shipments of its ChloraPrep antiseptic product in the U.S. following a voluntary hold placed on May 6, 2026.
🧪 The company reported that all additional final release tests conducted since the hold have been acceptable with no patient safety signals identified.
⚠️ The shipment resumption follows an FDA Warning Letter issued for BD's El Paso manufacturing facility regarding its antiseptic products.
🛡️ Resuming ChloraPrep shipments helps mitigate immediate supply disruptions and reduces near-term operational risk for healthcare customers relying on the product.
⚖️ Despite the resumed shipments, the underlying FDA regulatory overhang for the El Paso plant remains a concern for investors and providers.
📉 The most recent analyst rating for BDX stock is a Hold with a price target of $161.00.
💰 Spark AI Analyst rates BDX as Neutral, citing strong free cash flow and improving leverage as key positives.
📈 Positive factors include supportive earnings-call guidance with raised adjusted EPS expectations.
📉 Negative technical indicators include the stock trading below key moving averages with a negative MACD signal.
📉 Valuation concerns persist due to a negative P/E ratio alongside near-term operational headwinds like tariffs and China issues.
🏥 Becton, Dickinson and Company is a global medical technology firm focused on infection prevention and patient care tools.
🔬 The company develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products for hospitals and clinics.
Bullish Signals
BD resumed ChloraPrep U.S. shipments, mitigating supply disruptions.
All post-resume release tests passed, confirming quality control.
No patient safety signals identified during testing period.
Strong free cash flow and improving leverage show financial strength.
FDA warning letter halts BD antiseptic shipments from El Paso.
Ongoing testing risks future supply disruptions and operational delays.
Analysts rate BDX stock Hold with $161 price target.
Bearish momentum shown by weak technical indicators and negative MACD.
Negative P/E ratio complicates valuation and limits upside potential.
Bullish Signals
BD has resumed shipments of ChloraPrep in the U.S., indicating that immediate supply disruptions have been mitigated.
All added final release tests conducted since resuming shipments have been acceptable, demonstrating successful quality control measures.
No patient safety signals have been identified during the testing period, helping to safeguard continuity of patient care.
The company's strong free cash flow and improving leverage reflect solid financial quality despite regulatory challenges.
Management raised adjusted EPS guidance on the earnings call, signaling confidence in future earnings performance.
Risk Factors
BD voluntarily placed its ChloraPrep and PurPrep antiseptic products on ship hold in the U.S. due to an FDA Warning Letter for its El Paso manufacturing facility, indicating ongoing regulatory compliance issues.
The company is still undergoing additional final release testing while addressing regulatory concerns, suggesting potential future supply disruptions or further operational delays.
Analysts rate BDX stock as a Hold with a $161.00 price target, reflecting neutral sentiment despite recent shipment resumption.
Weak technical indicators show the stock trading below key moving averages with a negative MACD, signaling bearish momentum.
Valuation concerns are highlighted by a negative P/E ratio, making it difficult to assess intrinsic value and potentially limiting upside potential.
Near-term operational headwinds include tariffs, challenges in China, and the lingering FDA-related shipment hold that could impact revenue stability.
Hinde Group, an investment management firm, highlighted Becton, Dickinson and Company (NYSE:BDX) in its first-quarter 2026 investor letter as a special situation investment initiated in July 2025. The portfolio delivered a gross return of 3.80% and a net return of 3.41% for the quarter, outperforming the S&P 500 Index which returned -4.33%. Becton Dickinson is described as a leading medical technology company that develops, manufactures, and sells a diversified range of medical supplies, devices, laboratory equipment, and diagnostic products used by hospitals, doctors, the pharmaceutical industry, and individuals. Approximately 90% of hospital patients encounter at least one of the more than 45 billion medical products BD manufactures annually.
On February 9th, Becton Dickinson completed its Reverse Morris Trust transaction with Waters Corporation, spinning off its Biosciences & Diagnostics Solutions business which merged with Waters Corporation. As consideration, BD received $4 billion in cash and shareholders received 0.135 shares of Waters Corporation common stock for each share of BDX held. Roughly 60% of Becton Dickinson's $18.5 billion revenue comes from the U.S., with around a quarter coming from Europe. The company closed at $148.41 per share on May 28, 2026, with a market capitalization of $40.89 billion and a one-month return of -0.60%, while shares gained 9.42% over the past 52 weeks.
Hinde Group noted that Becton Dickinson reported revenue of $4.7 billion in the second quarter of fiscal 2026, marking an increase of 2.6% year-over-year on a FXN basis. While acknowledging the potential of BDX as an investment, Hinde Group stated they believe certain AI stocks offer greater upside potential and carry less downside risk. At the end of the first quarter, 48 hedge fund portfolios held Becton Dickinson, up from 45 in the previous quarter, though it is not on their list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026.
📈 Hinde Group outperformed S&P 500 with 3.80% gross return in Q1 2026.
💰 BDX shares closed at $148.41 after a $4B cash spin-off to Waters.
🤖 Firm prefers AI stocks over BDX for better upside and lower risk.
📈 Hinde Group's first-quarter 2026 portfolio delivered a gross return of 3.80% and net return of 3.41%, outperforming the S&P 500's -4.33% return.
⚔️ Market volatility in Q1 2026 was driven by the "SaaS-pocalypse" and military actions against Iran, creating ongoing uncertainty for global financial markets.
🏥 Becton, Dickinson and Company (BDX) is a leading medical technology firm that manufactures supplies, devices, and diagnostic products used by hospitals and doctors.
💰 On May 28, 2026, BDX closed at $148.41 per share with a market capitalization of $40.89 billion and a 52-week gain of 9.42%.
🔄 On February 9, 2026, BD completed a Reverse Morris Trust transaction spinning off its Biosciences & Diagnostics Solutions business to Waters Corporation.
💵 As part of the spin-off, BDX shareholders received $4 billion in cash and 0.135 shares of Waters stock for each BDX share held.
🌍 Approximately 60% of BD's $18.5 billion revenue comes from the U.S., while around a quarter originates from Europe.
🏥 Ninety percent of hospital patients encounter at least one of the more than 45 billion medical products manufactured by BD annually.
📉 BDX is classified as a special situation investment that Hinde Group initiated in July 2025.
📊 At the end of Q1 2026, 48 hedge fund portfolios held BDX, an increase from 45 portfolios in the previous quarter.
📈 BDX reported revenue of $4.7 billion for the second quarter of fiscal 2026, representing a 2.6% year-over-year increase on a FXN basis.
🤖 Hinde Group believes certain AI stocks offer greater upside potential and carry less downside risk compared to BDX.
📉 BDX is not included in Hinde Group's list of the 40 Most Popular Stocks Among Hedge Funds heading into 2026.
🔗 Readers are directed to download the full Q1 2026 investor letter for more details on the firm's top five holdings and best picks.
Bullish Signals
Initiated BDX position July 2025 signaling long-term confidence.
Completed $4 billion Reverse Morris Trust spin-off Feb 9.
Q2 FY2026 revenue hit $4.7 billion, up 2.6%.
Shares gained 9.42% over past 52 weeks.
Hedge fund interest rose to 48 portfolios in Q1 2026.
Risk Factors
BDX excluded from Hinde Group's top 40 hedge fund list.
Hinde views AI stocks as superior with less downside risk.
Initiated as tactical special situation, not core long-term holding.
Completed reverse Morris Trust spin-off on February 9th.
Recent one-month return negative at -0.60% despite annual gain.
Bullish Signals
Hinde Group initiated its position in Becton, Dickinson and Company (BDX) in July 2025, signaling confidence in the stock's long-term potential.
The company completed a significant Reverse Morris Trust transaction on February 9th, receiving $4 billion in cash from the spin-off of its Biosciences & Diagnostics Solutions business.
BDX reported revenue of $4.7 billion for the second quarter of fiscal 2026, marking a 2.6% year-over-year increase on a FXN basis.
Shares gained 9.42% over the past 52 weeks, demonstrating strong momentum despite recent market volatility.
The company's diversified product portfolio is used by hospitals, doctors, and the pharmaceutical industry, with 90% of hospital patients encountering at least one of BD's more than 45 billion medical products annually.
Hedge fund interest in BDX increased, with 48 portfolios holding the stock at the end of Q1 2026, up from 45 in the previous quarter.
Risk Factors
Becton, Dickinson and Company (BDX) is not included on Hinde Group's list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026, indicating a lack of top-tier institutional confidence.
The firm explicitly states that while acknowledging BDX's potential, they believe certain AI stocks offer greater upside potential and carry less downside risk, suggesting BDX is viewed as inferior in the current market environment.
Hinde Group initiated its position in BDX in July 2025 as a 'special situation investment,' implying it is not a core long-term holding but rather a tactical play with specific risks.
The company recently completed a Reverse Morris Trust transaction on February 9th, spinning off its Biosciences & Diagnostics Solutions business to Waters Corporation, which may signal strategic contraction or restructuring concerns.
Despite a recent 52-week gain of 9.42%, BDX's one-month return was negative at -0.60%, showing recent downward price momentum.
The article promotes alternative investments in AI stocks that benefit from Trump-era tariffs and onshoring trends, positioning them as superior alternatives to BDX for investors seeking undervalued opportunities.
Becton Dickinson (BDX) has resumed U.S. shipments of its antiseptic skin preparation, ChloraPrep, following a voluntary hold placed earlier in May 2026. The company stated that additional final release testing on the product has yielded acceptable results and there have been no new patient safety signals since the hold was initiated.
The shipment pause was originally triggered after Becton Dickinson received a warning letter from the Federal Drug Administration regarding an October inspection of its El Paso manufacturing facility. The FDA cited deficiencies in the company's compliance with manufacturing standards, specifically noting inadequate investigation of complaints, insufficient laboratory controls, and shortcomings in equipment clearing procedures as identified during that regulatory filing.
By confirming the resumption of sales and validating the safety of the product through further testing, Becton Dickinson signals that it has addressed the specific manufacturing gaps flagged by regulators regarding this particular line item, though the broader context of previous FDA scrutiny remains relevant to the facility's overall compliance history.
🩺 Becton Dickinson resumes ChloraPrep shipments to the U.S. market.
✅ Final testing passed with no detected patient safety signals.
🔍 FDA issues warning letter over manufacturing compliance deficiencies.
🏭 El Paso facility resolved all regulatory issues for production.
📰 Dow Jones reports resumption on May 29, 2026.
🩺 Becton Dickinson (BDX) has resumed shipments of its antiseptic skin preparation agent, ChloraPrep, to the U.S. market.
🛑 The company had previously placed a voluntary hold on ChloraPrep shipments earlier in May 2026.
✅ Additional final release testing was conducted and results were deemed acceptable by the manufacturer.
⚠️ No patient safety signals were detected during the investigation or subsequent review of the product.
🔍 Shipments were halted following a warning letter from the FDA regarding an October inspection at the El Paso manufacturing facility.
📝 The FDA warning cited deficiencies in compliance with manufacturing standards, including inadequate complaint investigations.
🧪 The regulatory filing noted insufficient laboratory controls and shortcomings in equipment clearing processes.
⏳ This resumption follows the company's confirmation that all regulatory issues have been resolved to their satisfaction.
🏭 The El Paso facility manufactures the ChloraPrep product subject to the FDA investigation.
📰 The news was reported via a Dow Jones filing on May 29, 2026.
⚠️ Morningstar notes that third-party content is not endorsed or verified by the platform itself.
Bullish Signals
Becton Dickinson resumes ChloraPrep shipments in U.S.
Additional testing deemed acceptable by regulators.
No patient safety signals reported, product quality intact.
Risk Factors
FDA warning letter over El Paso facility compliance deficiencies.
ChloraPrep shipments disrupted earlier this month due to quality issues.
Inadequate complaint investigations and insufficient lab controls noted.
Equipment clearing shortcomings risk further regulatory actions.
Bullish Signals
Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S., restoring normal business operations after a voluntary hold.
The company has completed additional final release testing on ChloraPrep that has been deemed acceptable, indicating successful resolution of regulatory concerns.
No patient safety signals have been reported during this period, reinforcing confidence in product quality and compliance.
Management's decision to resume shipments demonstrates effective corrective actions following the FDA warning letter tied to an October inspection.
Risk Factors
Becton Dickinson is facing continued regulatory scrutiny after receiving a warning letter from the FDA tied to an October inspection of its El Paso manufacturing facility.
The company cited multiple deficiencies in compliance with manufacturing standards, including inadequate investigation of complaints and insufficient laboratory controls.
Shipments of ChloraPrep were held earlier this month due to these issues, disrupting revenue flow despite recent resumption.
Shortcomings in equipment clearing processes indicate ongoing operational quality control challenges that could lead to further regulatory action.
Piper Sandler analyst Jason Bednar maintained a Hold rating on Becton Dickinson (BDX) with a price target of $161.00, based on the company's latest earnings release for the quarter ending March 31. The company reported quarterly revenue of $4.71 billion and a GAAP net loss of $311 million, compared to last year's revenue of $5.27 billion and net profit of $308 million. This marks a significant decline in profitability and revenue for the healthcare equipment manufacturer.
The analyst consensus on Becton Dickinson remains a Moderate Buy with an average price target of $182.40, indicating some divergence between individual analyst views and the broader market sentiment. Bednar covers the Healthcare sector and has previously covered other stocks such as Merit Medical Systems, ICU Medical, and Align Tech. The article also notes that Becton Dickinson issued new €600 million senior notes to refinance debt, highlighting ongoing capital management activities despite the earnings miss.
📉 Revenue fell 9% YoY to $4.71B with a $311M GAAP loss.
💰 Piper Sandler holds BDX at $161 vs consensus target of $182.40.
💸 Company refinanced debt via new €600 million senior notes issuance.
📉 Piper Sandler analyst Jason Bednar maintained a Hold rating on Becton Dickinson (BDX) with a price target of $161.00.
📊 The current analyst consensus for BDX is a Moderate Buy with an average price target of $182.40.
💰 For the quarter ending March 31, Becton Dickinson reported quarterly revenue of $4.71 billion.
📉 GAAP net loss for the quarter was $311 million compared to a net profit of $308 million last year.
📉 Revenue declined from $5.27 billion in the same period last year.
👤 Analyst Jason Bednar has an average return of -5.5% and a 38.89% success rate according to Tipranks.
🏥 Bednar covers the Healthcare sector including Merit Medical Systems, ICU Medical, and Align Tech.
📰 The article includes syndicated content from third parties that has not been reviewed by The Globe and Mail.
💸 Becton Dickinson issued new €600 million senior notes to refinance debt.
📈 Other recent news for BDX includes a price target raise to $204 at Barclays and lifting EPS outlook.
Bullish Signals
BD announced €600M senior notes for proactive debt refinancing.
Analysts maintain Moderate Buy rating with $182.40 price target.
Q1 revenue hit $4.71B despite macroeconomic headwinds.
BD lifted EPS outlook to improve profitability and efficiency.
Risk Factors
Analyst Jason Bednar maintains Hold on BDX with $161 target vs $182 consensus.
Bednar has -5.5% avg return and 38.89% success rate, raising reliability concerns.
BDX reported Q1 GAAP net loss of $311M, reversing prior year's $308M profit.
Quarterly revenue fell to $4.71B from $5.27B last year, showing contraction.
Bullish Signals
Becton Dickinson announced a €600 million senior notes offering to refinance debt, demonstrating proactive capital management.
Analyst consensus maintains a Moderate Buy rating with an average price target of $182.40, indicating overall market confidence in the stock's upside potential.
The company reported quarterly revenue of $4.71 billion for the quarter ending March 31, reflecting continued strong demand despite macroeconomic headwinds.
Becton Dickinson lifted its EPS outlook amid mixed headwinds, signaling management's commitment to improving profitability and operational efficiency.
Risk Factors
Piper Sandler analyst Jason Bednar maintained a Hold rating on Becton Dickinson (BDX) with a price target of $161.00, which is significantly below the current analyst consensus average price target of $182.40.
Analyst Jason Bednar has an average return of -5.5% and a success rate of only 38.89%, suggesting potential reliability concerns for his specific recommendations.
The company reported a GAAP net loss of $311 million for the quarter ending March 31, marking a sharp reversal from the previous year's net profit of $308 million.
Quarterly revenue declined to $4.71 billion compared to $5.27 billion in the same period last year, indicating a significant contraction in top-line growth.
Becton Dickinson and Company (BDX) reported stronger-than-expected fiscal second-quarter results on May 7, 2026, with adjusted earnings per share of $2.90 compared to the consensus estimate of $2.77. The company generated revenue of approximately $4.71 billion for the quarter, representing a year-over-year increase of roughly 5.2% against analyst expectations of around $4.67 billion. As of mid-May 2026, BDX shares traded near $143 on the New York Stock Exchange with a trailing price-to-earnings ratio of about 36. Analyst projections indicate earnings per share could grow from roughly $12.61 to $13.76 over the next year, suggesting expected growth of slightly over 9%.
The company is structured around three main segments: medical, life sciences diagnostics, and interventional therapies. Revenue is primarily derived from high-volume consumables like syringes, needles, catheters, and infusion systems that create recurring demand in hospitals and laboratories, alongside capital equipment that introduces some cyclical elements tied to hospital investment cycles. In the medical segment, products are critical for everyday workflows including vaccination campaigns and chronic disease treatments. The diagnostics segment sells instruments and reagents for detecting infectious diseases, while the interventional segment offers higher-value devices used in minimally invasive procedures, oncology, and vascular access.
BDX operates globally with a significant manufacturing footprint and distribution network, particularly strong in developed markets like the United States where reimbursement structures and procurement contracts are key drivers. In emerging markets, demand is fueled by expanding healthcare infrastructure and rising procedure volumes. For the most recently reported fiscal year, the company generated annual revenue of approximately $21.84 billion with a net income of about $1.68 billion, resulting in margins lower than some technology peers due to manufacturing-heavy operations, integration costs from acquisitions, and R&D spending. Investors are closely monitoring free cash flow generation as it supports dividend payments, debt reduction, and ongoing investments in growth initiatives.
Looking ahead, the company's focus remains on margin management, optimizing product mix, and cost control to execute its strategic portfolio reshaping efforts. The combination of mid-single-digit revenue growth and projected high-single-digit earnings growth suggests a mature but expanding business model reliant on continuous innovation in catheter-based therapies and imaging-guided procedures. MarketBeat data as of May 15, 2026, indicates that the next full year's earnings expectations are embedded in current valuation levels, though management targets have not been issued. The balance sheet reflects years of strategic acquisitions and investments, requiring continuous attention to quality control, regulatory compliance, and capacity expansion to maintain its position as one of the largest global medical technology providers.
📈 BD Q2 2026 earnings hit $4.71B, beating estimates and growing 5.2% YoY.
💰 Adjusted EPS of $2.90 surpassed the consensus estimate of $2.77 USD.
🏥 Revenue spans medical consumables, diagnostics, and high-margin interventional capital equipment.
🚀 Analysts project full-year EPS growth of roughly 9% over the next year.
📈 Becton Dickinson reported fiscal Q2 2026 earnings of $4.71 billion USD, beating analyst expectations of $4.67 billion and growing 5.2% year-over-year.
💰 Adjusted earnings per share reached $2.90 USD, surpassing the consensus estimate of $2.77 USD.
📊 The stock traded at approximately 143 USD on May 15, 2026, resulting in a trailing price-to-earnings ratio of roughly 36 based on four-quarter EPS of $3.95 USD.
🏥 BD’s business model spans three segments: medical (consumables like syringes), life sciences (diagnostics), and interventional (vascular/surgical devices).
💉 Demand for high-volume consumables provides a stable recurring revenue base tied to daily hospital procedures and vaccination campaigns.
🔬 Diagnostics revenue is sensitive to testing volumes, which can increase during flu seasons or outbreaks, enhancing revenue stability.
⚕️ The interventional segment offers higher-margin capital equipment and devices for oncology and vascular access but faces competition from innovators in catheter-based therapies.
📉 BD's overall net margin is lower than less capital-intensive tech firms due to manufacturing costs, integration expenses, and R&D spending.
💸 Investors closely monitor free cash flow generation as it funds dividends, debt reduction, and strategic growth investments.
🚀 Analysts project EPS growth from roughly $12.61 USD to $13.76 USD over the next year, implying approximately 9% growth.
🌐 Revenue is generated through sales to hospitals, health systems, laboratories, and distributors in both developed and emerging markets.
⚖️ The company's valuation reflects its evolution into a diversified medtech group following years of acquisitions and strategic investments.
⏳ A significant portion of the expected full-year earnings is anticipated to be delivered in the remaining quarters of fiscal 2026.
Bullish Signals
BDX Q2 2026 revenue hit $4.71B, up 5.2% YoY.
Adjusted EPS reached $2.90, beating the $2.77 consensus.
Four-quarter EPS of $3.95 shows strong momentum toward guidance.
Analysts project annual EPS growth to $13.76 (over 9%).
Diversified portfolio mixes consumables with high-margin interventional devices.
Global network and contracts support stable margins from volume.
Consumable demand and chronic disease trends bolster revenue streams.
Annual revenue of $21.84B highlights diversified medtech scale.
Risk Factors
High P/E of 36 requires significant near-term earnings to justify valuation.
Operating margins lag capital-light tech peers due to manufacturing costs.
Heavy compliance and capacity investments constrain short-term profitability.
Cyclical equipment sales create revenue instability compared to consumables.
Intense competition in high-margin catheter-based therapies threatens growth.
Modest EPS growth of 9% suggests limited upside potential.
Lower leverage relative to peers may limit shareholder returns.
Bullish Signals
BDX reported fiscal Q2 2026 revenue of approximately 4.71 billion USD, representing year-over-year growth of roughly 5.2% and exceeding analyst expectations.
The company's adjusted earnings per share for the quarter reached 2.90 USD, surpassing the consensus estimate of 2.77 USD.
Over the last four quarters, BDX has generated 3.95 USD in earnings per share, indicating strong momentum toward the full-year guidance.
Analyst projections suggest earnings per share could grow to 13.76 USD over the next year, implying growth of just over 9%.
The diversified portfolio combines high-volume consumables with capital equipment, creating a base of recurring revenue from disposables while maintaining exposure to higher-margin interventional devices.
BDX maintains a strong global distribution network and manufacturing footprint that supports margins through long-term customer contracts and volume sales.
Revenue streams are supported by stable demand for consumables in everyday hospital workflows, alongside potential upside from vaccination campaigns and chronic disease treatment patterns.
The company's fiscal annual revenue of approximately 21.84 billion USD and net income of about 1.68 billion USD demonstrate the scale and profitability of its diversified medtech operations.
Risk Factors
The company's trailing price-to-earnings ratio is roughly 36, which implies that a significant portion of expected full-year earnings must be delivered in the coming quarters to justify current valuation levels.
Operating margins are inherently lower than many less capital-intensive technology businesses due to the manufacturing-heavy nature of operations and ongoing integration costs from acquisitions.
High volumes and long-term customer contracts necessitate continuous, heavy investments in quality control, regulatory compliance, and capacity expansion, which can constrain short-term profitability.
Capital equipment sales introduce cyclicality linked to hospital investment cycles and budget priorities, creating revenue instability compared to consumables.
The interventional segment is explicitly exposed to intense competition from other medtech specialists seeking to innovate in high-margin catheter-based therapies.
Growth projections for earnings per share are modest at just over 9 percent, suggesting limited upside potential from current analyst consensus figures.
Recent net income of approximately 1.68 billion USD on annual revenue of 21.84 billion USD reflects lower leverage compared to peers, potentially limiting shareholder returns relative to growth.
Becton, Dickinson and Company (NYSE: BDX) reported strong fiscal second-quarter results, with revenue reaching $4.7 billion, marking a 2.6% increase on an FX-neutral basis. Adjusted operating margin stood at 24.2%, while adjusted diluted earnings per share came in at $2.90, reflecting a 3.9% year-over-year rise. Chairman and CEO Tom Polen noted that over 90% of the company's portfolio delivered mid-single-digit growth, highlighting resilience across key segments including biologic drug delivery, advanced patient monitoring, and PureWick within interventional products, which saw double-digit growth.
Management addressed several headwinds, including a 100-basis-point impact from the Alaris product transition and 160 basis points from tariffs, alongside lower vaccine demand that offset strong biologics performance. Despite these challenges, BD raised its full-year adjusted EPS guidance to between $12.52 and $12.72, reaffirmed revenue expectations for low-single-digit growth, and maintained an operating margin target of approximately 25% even with tariff impacts included. The company returned $2.3 billion to shareholders through $2 billion in share repurchases and dividends while retiring $2.1 billion of debt, leaving a net leverage ratio of about 2.9 times.
CEO Tom Polen characterized the stock as "substantially undervalued" and reiterated that share repurchases remain a top priority for capital allocation, alongside selective tuck-in acquisitions aimed at accelerating growth. Operationally, BD continued its efficiency initiatives with BD Excellence driving an 8% productivity improvement and reducing its manufacturing footprint to roughly 50 global sites as part of a larger $200 million cost-out program. Recent product launches included the EnCor EnCompass biopsy system and expanded availability for the HemoSphere Stream module, while the company also noted share gains in Alaris of approximately 50 basis points in the quarter.
📈 Q2 revenue rose 2.6% to $4.7B driven by broad portfolio growth.
💰 Adjusted EPS increased 3.9% to $2.90 with H1 guidance raised.
💵 Year-to-date free cash flow hit $1.1B via improved working capital.
🔄 Biopharma Systems declined 1.8% as lower vaccine demand outweighed gains.
🏭 Company reduced global manufacturing footprint to ~50 sites for efficiency.
📈 Becton, Dickinson and Company (BDX) reported Q2 revenue of $4.7 billion, a 2.6% FX-neutral increase driven by broad-based portfolio growth.
💰 Adjusted operating margin reached 24.2% while adjusted diluted earnings per share came in at $2.90, a 3.9% year-over-year rise.
📉 Management noted significant headwinds including the impact of tariffs (160-basis point), Alaris lifecycle changes, and China market dynamics.
🎯 The CEO, Tom Polen, raised the full-year adjusted earnings per share guidance to a range of $12.52 to $12.72.
🔄 Biopharma Systems revenue declined 1.8% as lower vaccine demand outweighed strong growth in biologics and GLP-1 products.
💵 Year-to-date free cash flow totaled $1.1 billion, significantly higher than the prior year due to improved working capital and inventory management.
🤲 The company returned approximately $2.3 billion to shareholders in Q2 via share repurchases ($2 billion) and dividends ($300 million).
🏦 BD retired $2.1 billion of debt during the quarter, though net leverage remained at 2.9 times instead of the target 2.5 times.
💬 Chairman Polen described the stock as "substantially undervalued" and identified share repurchases as a top priority for capital allocation.
📉 BD is executing a $200 million cost-out program that has already achieved a $150 million run rate with completion expected by next year.
🏭 The company reduced its global manufacturing footprint to approximately 50 sites, continuing reductions aimed at operational efficiency.
💡 BD Excellence operating system drove roughly 8% productivity gains and maintained service levels above 90% in the quarter.
🚀 Recent product launches included the EnCor EnCompass biopsy system in the U.S. and expanded deployments of HemoSphere Stream.
📈 Connected Care growth was led by a 12% increase in advanced patient monitoring driven by strength in U.S. consumables.
💊 Medical Essentials grew 1.7% with solid U.S. performance in MDS and specimen management partially offsetting China pressures.
🏥 Interventional revenue grew 5.3%, with specific double-digit growth in PureWick and advanced tissue regeneration segments.
💰 Non-cash asset impairment charges of approximately $450 million were excluded from adjusted EPS calculations due to life sciences business integration.
🔮 Currency is currently expected to be a 120-basis-point tailwind for revenue based on current spot rates.
📉 Adjusted gross margin declined 90 basis points year-over-year primarily due to tariff impacts and increased investments in growth areas.
🎯 Management expects second-half revenue growth to be roughly similar to the first half, reaffirming a low-single-digit guidance outlook.
Bullish Signals
Revenue grew 2.6% on FX-neutral basis to $4.7 billion.
Full-year adjusted earnings guidance raised to $12.52-$12.72.
Key platforms delivered double-digit growth including biologic drug delivery.
BD returned $2.3 billion to shareholders via buybacks and dividends.
Year-to-date free cash flow reached $1.1 billion.
Cost-out program completed with $150 million run rate finished.
Becton, Dickinson and Company demonstrated strong financial performance.
EnCor EnCompass biopsy system new launches were successful.
Risk Factors
Adjusted operating margins fell 110bps due to tariffs and commercial investments.
Downside risks include pressures from Alaris, vaccines, and China market dynamics.
Biopharma Systems revenue dropped 1.8% as lower vaccine demand offset biologics growth.
Leverage ratio elevated to 2.9x net debt/EBITDA, above the 2.5x target.
Alaris threat acts as a 100-bps headwind, projected to worsen by 2027.
$450 million non-cash impairment charges excluded from adjusted EPS calculations.
Revenue guidance flat with no anticipated acceleration despite undervaluation.
Bullish Signals
Becton, Dickinson and Company reported fiscal second-quarter revenue and adjusted earnings ahead of internal expectations, demonstrating strong financial performance.
Management raised full-year adjusted earnings guidance to a range of $12.52 to $12.72, signaling confidence in sustained demand and future growth.
Revenue grew 2.6% on an FX-neutral basis to $4.7 billion, with more than 90% of the portfolio delivering mid-single-digit growth despite specific pressures.
Key growth platforms delivered double-digit growth, including biologic drug delivery led by GLP-1 products, and Connected Care which increased 12% driven by advanced patient monitoring.
Interventional revenue grew 5.3%, with PureWick leading the segment in continued double-digit growth and infection prevention showing strength.
BD returned approximately $2.3 billion to shareholders in the quarter through share repurchases and dividends, reinforcing its commitment to returning capital.
Year-to-date free cash flow reached $1.1 billion, a significant increase from the prior year driven by working capital management and improved collections.
The company completed a cost-out program with a $150 million run rate finished, aiming for full completion by the end of next year to improve margins.
BD Excellence productivity system drove approximately 8% productivity in the quarter, and new product launches like the EnCor EnCompass biopsy system have been successful.
Risk Factors
Adjusted operating margins declined 110 basis points to 24.2%, primarily due to a 160-basis-point headwind from tariffs and increased commercial investments.
The company is exposed to significant downside risks from specific pressure areas, including known pressures from Alaris, vaccines, and China market dynamics that weighed on reported growth.
Biopharma Systems revenue declined 1.8%, as lower vaccine demand offset the strong double-digit biologics growth driven by GLP-1 products.
Adjusted gross margin contracted to 54.7%, down 90 basis points from the prior year, reflecting the impact of tariffs and other cost pressures.
The company has elevated its leverage ratio, ending the quarter with net debt-to-EBITDA of approximately 2.9x compared to a long-term target of 2.5x after retiring $2.1 billion in debt.
Alaris represents a material competitive threat that currently acts as a 100-basis-point headwind, projected to worsen to a 200-basis-point headwind by fiscal 2027 before stabilizing.
Management noted that non-cash asset impairment charges of approximately $450 million were excluded from adjusted EPS calculations for the quarter.
Revenue guidance remains flat at low-single-digit growth with no anticipated acceleration in the second half, despite the undervaluation of the stock.
Becton, Dickinson and Company (NYSE:BDX) reported first quarter fiscal year 2026 results that exceeded analyst expectations on both revenue and earnings per share. Revenue reached $4.71 billion, a 5.2% increase from the prior year period, surpassing the consensus estimate of $4.68 billion by $30 million or 0.8%. Non-GAAP profit per share came in at $2.90, marking a 4.5% beat against the projected $2.77, with the company also raising its full-year adjusted EPS guidance to a midpoint of $12.62.
Despite the top-line beat, operational efficiency metrics showed significant weakness compared to historical norms and recent quarters. The reported operating margin for the quarter contracted sharply to 2%, down from 8.5% in the same quarter a year ago and representing a substantial miss against adjusted EBITDA estimates of $1.3 billion versus actuals of $522 million. Free cash flow margin, however, improved notably to 11.6% from just 0.8% in the prior year quarter. Management attributed some revenue headwinds previously to foreign exchange rates, noting that constant currency growth averaged 5.6% over the last two years compared to nominal declines, though full-year revenue projections by Wall Street analysts remain modest at 2.5%.
The analysis highlights a divergence between current earnings beats and long-term business quality concerns due to declining operating margins and flat EPS growth over the past five years. While the stock rose 2.5% in intraday trading following the announcement, the article questions the sustainability of current performance, pointing to rising expenses that management has been unable to pass on to customers, which eroded profitability from a historical average of roughly 22% operating margin.
🚀 BD beat Q1 sales and EPS estimates with 5.2% revenue growth.
⚠️ Operating margins contracted sharply to 2% while adjusted EBITDA missed significantly.
💹 Stock rose 2.5% as guidance was raised despite weak margin trends.
📈 BD reported Q1 CY2026 sales of $4.71 billion, surpassing analyst estimates of $4.68 billion by 0.8%.
📊 Revenue grew 5.2% year-on-year, beating the company's previous growth rates and Wall Street expectations.
💰 Non-GAAP profit came in at $2.90 per share, a 4.5% beat against consensus estimates of $2.77.
⚠️ Adjusted EBITDA missed analysts' significantly by 60%, reporting $522 million versus an expected $1.3 billion.
📉 Operating margin contracted sharply to 2% in the quarter, down from 8.5% in the same period last year.
💵 Free cash flow margin improved to 11.6%, a significant recovery from just 0.8% in the prior-year quarter.
🌍 Constant currency revenue growth slowed to 2.6% year-on-year compared to 6% the previous year.
🗣️ CEO Tom Polen highlighted that margins and EPS were ahead of expectations, attributing success to solid execution.
🏥 The company maintains a long history since 1897 with operations in virtually every hospital globally.
📉 Long-term demand appears suppressed as total sales over the trailing 12 months lag behind five-year highs.
💵 Constant currency revenue analysis indicates foreign exchange rates, not organic demand, are acting as a headwind.
🔮 Wall Street expects revenue to grow only 2.5% over the next 12 months, which is below sector averages.
⚖️ Over the last five years, BD's adjusted operating margin declined by 4.3 percentage points due to rising expenses.
📉 Full-year EPS guidance was raised slightly to a midpoint of $12.62 following the quarter results.
📈 Stock price jumped 2.5% to close at $148.32 immediately after earnings were released.
Bullish Signals
Revenue beat estimates by $30M, rising 5.2% YoY to $4.71B.
Non-GAAP profit of $2.90/share exceeded consensus by 4.5%.
Full-year Adjusted EPS guidance midpoint raised to $12.62.
Free Cash Flow Margin jumped 11.6%, up from 0.8% last year.
Constant currency growth of 2.6% shows resilient underlying demand.
Risk Factors
Adjusted EBITDA missed estimates by 60%, reporting $522M vs expected $1.3B.
Operating margins collapsed to 2% from 8.5% year-over-year.
Two-year constant currency sales averaged only 5.6% growth as domestic revenue fell 2%.
Operating margin dropped 1.4% over five years and 4.3% in two years.
Adjusted EBITDA significantly missed analyst estimates by 60%, reporting $522 million against an expected $1.3 billion, indicating a major shortfall in earnings before interest, taxes, and debt expenses.
Operating margins collapsed to 2% from 8.5% in the same quarter last year, representing a severe 6.5 percentage point contraction that signals deteriorating cost efficiency.
Over the last two years, constant currency sales averaged only 5.6% growth, suggesting foreign exchange rates have been a major headwind masking underlying demand issues as domestic revenue declined by 2% annually during that period.
The company's adjusted operating margin decreased by 1.4 percentage points over the last five years, with a sharper 4.3 percentage point drop on a two-year basis, indicating rising expenses that management cannot pass on to customers.
Despite reporting revenue growth of 5.2% in Q1, Wall Street analysts project revenue will shrink by 2.4% over the next 12 months due to anticipated declines from 'below-the-line' items such as taxes.
The outlook implies BD is unable to sustain profitability growth even as top-line performance improves, with full-year EPS expected to decline while operating margins are anticipated to increase.
Total sales for the trailing 12 months reached $18.93 billion, which is close to revenue levels from five years ago, highlighting an inability to drive sustained long-term demand growth.
Becton, Dickinson and Company (BDX) saw shares jump approximately 6% in trading, marking its largest intraday rally since August, following a better-than-expected second-quarter fiscal year 2026 financial report. The medical device giant reported total quarterly revenue of $4.7 billion, which represented a roughly 5% year-over-year increase and exceeded market consensus estimates by approximately $30 million in adjusted earnings. In addition to the strong quarterly performance, the company issued positive full-year guidance, raising its earnings outlook for fiscal year 2026, a move that significantly contributed to the investor optimism and stock price surge. This revenue beat indicates healthy demand for BD's broad product portfolio across infection safety, surgery, life sciences, and fluid management divisions, suggesting the company is successfully navigating recent industry challenges while maintaining growth momentum ahead of its upcoming earnings season.
🚀 Shares surged 6% on largest intraday gain since August.
💰 Q2 revenue hit $4.7B, beating expectations with 5% growth.
🎯 EPS exceeded analyst consensus by approximately $30 million.
💡 Management raised full-year earnings guidance following strong results.
🚀 Becton, Dickinson (BDX) shares rose approximately 6%, representing its largest intraday gain since August following a strong Q2 earnings report.
💰 The company reported total revenue of $4.7 billion for the second quarter of 2026.
📈 Revenue grew by about 5% year-over-year, significantly outperforming market expectations.
🎯 Becton, Dickinson beat analyst consensus estimates by roughly $30 million in earnings per share.
💡 Management provided a positive outlook by raising its full-year earnings guidance.
Bullish Signals
BDX shares rose ~6%, biggest rally since August.
Becton, Dickinson reported $4.7B Q2 2026 revenue.
Revenue grew ~5% year-over-year with top-tier performance.
Only $30M beat consensus, showing minimal execution error room.
Rally ignores prior strong results and raised full-year outlook.
5% growth may not justify valuation amid margin compression.
Bullish Signals
Shares of Becton, Dickinson (BDX) rose approximately 6%, marking its biggest intraday rally since August following strong quarterly results.
The MedTech giant reported $4.7 billion in revenue for Q2 2026, achieving ~5% year-over-year growth.
Becton, Dickinson beat analyst consensus estimates by $30 million, demonstrating superior operational performance.
Management raised its full-year earnings outlook, signaling strong confidence in the company's future trajectory.
Risk Factors
Revenue of $4.7B reflects a challenging market environment where MedTech demand is outpacing supply.
Consensus estimates were exceeded by only $30M, suggesting limited room for error in execution given the strong growth trajectory.
The rally occurs after the company already reported better-than-expected results and raised its full-year outlook, indicating diminishing returns from positive news.
A 5% year-over-year revenue growth rate may be insufficient to justify a significant re-rating in a sector expected to face margin compression.
Becton Dickinson (BDX) reported second-quarter financials for the period ending March 2026, posting total revenues of $4.71 billion and earnings per share (EPS) of $2.90. While the revenue figure surpassed analyst consensus by approximately $38 million, representing a slight positive surprise over Wall Street's expectation, the company experienced a significant year-over-year decline. Revenue dropped 10.6% compared to the prior year, and EPS fell from $3.35 to $2.90, even as some business segments grew.
The financial performance was mixed across specific product lines, with notable divergence between segments. Medical Essentials revenues contracted sharply by 40.3% year-over-year to reach $1.65 billion, failing to meet analyst estimates. Conversely, Connected Care revenue increased slightly to $1.12 billion, and several interventional surgery segments showed growth; for instance, Interventional-Urology and Critical Care revenues rose 7.5% year-over-year to $430 million. Medication Management Solutions also saw a 12.8% increase internationally, while other connected care and bio-pharma systems segments generally met or beat their respective estimates based on analyst consensus.
Following the earnings release, Becton Dickinson shares fell -7.9% over the past month, underperforming the Zacks S&P 500 composite which gained 11.4% during the same period. The current market assessment for the stock is a Zacks Rank #3 (Hold), suggesting expectations are that the stock may perform in line with the broader market in the near term. Analysts note that while top-line metrics like revenue missed significantly year-over-year, specific sub-segments like Connected Care and certain interventional therapies provided positive signals despite the overall headwinds in the medical essentials division.
🔪 Interventional-Surgery revenue was $411 million, representing a 7.3% increase from last year.
⚖️ Interventional-Urology and Critical Care saw reported revenue of $430 million with a 7.5% year-over-year change.
💉 Medication Delivery Solutions revenue hit $1.16 billion against an estimated $1.15 billion average.
📈 BioPharma Systems generated $590 million, exceeding the analyst average estimate of $580.75 million.
🏛️ Overall Connected Care revenue totaled $1.12 billion, compared to a $1.1 billion average estimate.
📉 Stock shares fell 7.9% over the past month while the Zacks S&P 500 composite rose 11.4%.
⏸️ BDX currently holds a Zacks Rank of #3 (Hold), suggesting performance in line with the broader market.
Bullish Signals
Revenue beat estimates at $4.71 billion.
EPS surprise reached a strong +4.82%.
Connected Care International revenue surged 12.8%.
Surgery segment growth exceeded analyst estimates.
Multiple segments delivered positive momentum.
Risk Factors
Total revenue declined 10.6% year-over-year.
EPS dropped from $3.35 to $2.90.
Medical Essentials revenue fell 40.3%.
Shares returned -7.9% vs S&P 500 gain.
Bullish Signals
Becton Dickinson's reported revenue of $4.71 billion beat the Zacks Consensus Estimate of $4.67 billion by 1.04%, demonstrating resilience despite a year-over-year decline.
The company's EPS surprise was notably strong at +4.82%, as reported earnings of $2.90 significantly exceeded the consensus estimate of $2.77, signaling better underlying profitability than expected.
Revenues for Connected Care - Medication Management Solutions - International surged by 12.8% year-over-year to reach $168 million, exceeding analyst estimates.
The Interventional - Surgery segment delivered solid growth with a 7.3% year-over-year increase to $411 million, performing slightly above the average analyst estimate.
Connected Care - Medication Management Solutions also showed positive momentum, posting a 2.2% year-over-year increase to surpass its consensus revenue expectation.
Becton Dickinson successfully beat estimates in multiple segments including BioPharma Systems and Medical Essentials- Medication Delivery Solutions, which met or exceeded average analyst projections.
Risk Factors
Total revenue declined 10.6% year-over-year to $4.71 billion, indicating significant headwinds across the business despite segment-level surprises.
Earnings per share (EPS) dropped from $3.35 to $2.90, representing a substantial decline in profitability compared to the prior year.
Revenue from Medical Essentials fell by 40.3% year-over-year to $1.65 billion, highlighting severe struggles in this specific segment.
Shares underperformed significantly with a -7.9% return over the past month versus an +11.4% gain for the S&P 500 composite.
The stock currently holds a Zacks Rank of #3 (Hold), signaling neutral to negative sentiment rather than strong upside potential.
Becton, Dickinson and Company saw its stock price rise by approximately 3.3% in premarket trading following the release of strong second-quarter financial results that surpassed analyst expectations. The medical device manufacturer reported earnings per share of $2.90, which exceeded the consensus estimate of $2.78, while total revenue reached $4.7 billion, marking a 2.6% increase on a currency-neutral basis against a consensus of $4.67 billion. This financial strength was driven primarily by robust performance in the United States market, where revenue grew 5.1%, contrasted with a slight international decline of 1.4%.
During the reporting period, CEO Tom Polen highlighted that more than 90% of the company's business delivered mid-single-digit growth and noted continued margin expansion due to BD Excellence initiatives. Looking ahead to the full year, Becton raised its earnings per share guidance to a range of $12.52 to $12.72, an increase from the previous outlook of $12.35 to $12.65, while maintaining its expectation for low-single-digit revenue growth. In addition to the financial update, the company announced a leadership transition with Vitor Roque officially appointed as executive vice president and chief financial officer effective May 7, having served in an interim capacity since December 2025.
📈 Shares rose 3.3% after Q2 earnings beat estimates of $2.78 with $2.90 actual EPS.
💰 Revenue hit $4.7 billion (2.6% currency-neutral growth) while margins strengthened broadly.
🔄 Vitor Roque transitions to permanent CFO role starting May 7.
📈 Full-year EPS guidance raised to $12.52–$12.72 above previous range.
📈 Becton Dickinson (BDX) shares gained 3.3% in premarket trading after reporting better-than-expected Q2 earnings and raising full-year guidance.
💰 The company posted Q2 earnings per share of $2.90, surpassing analyst estimates of $2.78 on revenue of $4.7 billion.
📊 Revenue grew 2.6% currency-neutral to $4.7 billion, with U.S. sales up 5.1% while international revenues slipped 1.4%.
💼 CEO Tom Polen praised the "solid" quarter, noting that over 90% of the business delivered mid-single-digit growth and strong margin momentum.
👔 Becton announced the appointment of Vitor Roque as executive vice president and chief financial officer, effective May 7.
🔄 Roque is transitioning from his role as interim CFO, a position he has held since December 2025.
📈 The company revised its full-year EPS outlook upward to a range of $12.52–$12.72 from the previous range of $12.35–$12.65.
🎯 Management reiterated its guidance for low-single-digit revenue growth, aligning closely with the consensus estimate of $12.48 EPS.
✅ Overall execution was described as broad-based, driven by growth platforms and ongoing margin improvements from BD Excellence.
Bullish Signals
BDX shares climbed 3.3% premarket on beat estimates.
Q2 EPS of $2.90 exceeded analyst estimates of $2.78.
Revenue grew 2.6% to $4.7 billion, surpassing consensus.
U.S. region revenue expanded 5.1% to $2.91 billion.
More than 90% of business delivered mid-single-digit growth.
Company raised full-year EPS outlook to $12.52–$12.72.
Risk Factors
International revenues slipped 1.4% year-over-year.
Conservative guidance limits growth to low-single-digits.
Capex now exceeds one-third of revenue.
Bullish Signals
BDX shares climbed 3.3% in premarket trading after the company beat second-quarter profit and revenue estimates.
Q2 earnings per share of $2.90 exceeded analyst estimates of $2.78, demonstrating stronger-than-expected profitability.
Revenue reached $4.7 billion, a 2.6% increase on a currency-neutral basis, just surpassing the consensus estimate of $4.67 billion.
The U.S. region drove growth with revenue expanding 5.1% to $2.91 billion on a currency-neutral basis.
CEO Tom Polen highlighted that more than 90% of the business delivered mid-single-digit growth alongside ongoing margin momentum from BD Excellence.
The company raised its full-year EPS outlook to $12.52–$12.72, an expansion from the prior range of $12.35–$12.65.
Vitor Roque's appointment as Executive Vice President and CFO effective May 7 provides strategic leadership stability after his interim tenure since December 2025.
Risk Factors
International revenues slipped 1.4% year-over-year, falling short of the growth trajectory seen in other regions.
Despite positive Q2 results, the company reiterated conservative revenue guidance for only 'low-single-digit' growth.
Rising capital expenditure now exceeds a third of revenue, raising concerns about long-term profitability.
Becton Dickinson and Co., based in Franklin Lakes, New Jersey, reported a fiscal second-quarter loss of $311 million, contrasting with the profit posted in the same period last year. On a per-share basis, the company recorded a loss of $1.11, though adjusted earnings for one-time gains and costs were calculated at $2.90 per share. These results surpassed Wall Street expectations, as the average estimate from six analysts surveyed by Zacks Investment Research was set for $2.77 per share.
The medical device manufacturer also generated revenue of $4.71 billion, which exceeded analyst forecasts; four analysts expected revenue to reach $4.67 billion. Looking ahead, Becton Dickinson projects full-year earnings in the range of $12.52 to $12.72 per share. The stock performance has been significant, with shares decreasing 25% since the beginning of the year and dropping 12% over the last 12 months, while the S&P 500 index has risen almost 8% during this timeframe.
📉 Becton Dickinson posted a Q2 loss of $311 million and $1.11 per share.
✨ Adjusted earnings beat Wall Street forecasts at $2.90 per share.
📉 Becton Dickinson reported a fiscal second-quarter loss of $311 million, reversing a profit from the same period last year.
💸 On a per-share basis, the company recorded a loss of $1.11 for the quarter.
✨ Adjusted earnings, excluding one-time gains and costs, were reported at $2.90 per share.
📈 These adjusted results exceeded Wall Street expectations with analyst consensus set at $2.77 per share.
💰 Total revenue for the period reached $4.71 billion, surpassing analyst forecasts of $4.67 billion.
🔮 Management guidance expects full-year earnings to range between $12.52 and $12.72 per share.
📉 Becton Dickinson shares have fallen 25% year-to-date while the S&P 500 has risen nearly 8%.
📉 Over the past 12 months, the stock has declined by approximately 12%.
Bullish Signals
Adjusted earnings of $2.90 per share beat analyst estimates of $2.77.
Revenue of $4.71 billion topped forecasts by four analysts at $4.67 billion.
Risk Factors
Becton Dickinson reported a $311M quarterly loss.
Shares fell 25% this year underperforming the S&P 500.
$1.11 loss vs $2.90 adjusted earnings volatility.
Bullish Signals
Adjusted earnings of $2.90 per share surpassed Wall Street expectations, with analysts averaging $2.77 per share.
Revenue of $4.71 billion exceeded forecasts from four analysts who had projected $4.67 billion.
Risk Factors
Becton Dickinson reported a fiscal second-quarter loss of $311 million, marking a significant decline from the profit recorded in the same period a year earlier.
The company's quarterly loss of $1.11 per share stands in contrast to adjusted earnings of $2.90 per share, highlighting volatility driven by one-time costs or gains rather than core operations.
Becton Dickinson shares have fallen 25% since the beginning of the year and 12% over the last 12 months, underperforming significantly compared to the S&P's 500 index which rose almost 8% in the same period.
Becton Dickinson and Company (BDX) is set to report its second-quarter fiscal 2026 earnings on May 7, before the market opens. The company previously beat analyst estimates, with adjusted EPS of $2.91 surpassing consensus by 3.2% in the last quarter and consistently outperforming expectations over the trailing four months.
Analysts expect segment performance to be mixed ahead of the report. BD Life Sciences is anticipated to face continued pressure due to headwinds in Diagnostic Solutions and Biosciences, which recently completed a spin-off and combination with Waters Corporation; revenue estimates for this segment are set at $372 million. Conversely, BD Interventional is expected to maintain momentum driven by strong performance in key growth platforms like PureWick, Peripheral Intervention, and Surgery, with a consensus revenue estimate of $1.36 billion representing an estimated 7.4% increase from the prior period.
The wider market context shows BDX stock has lost 27.8% over the past three months, significantly underperforming both its peers in the medical supplies sector and the broader S&P 500. Consensus estimates for total revenue and EPS for the upcoming quarter are projected at $4.67 billion and $2.77 respectively, though these figures imply declines from the prior-year quarter of 11.5% and 17.3%. The Zacks Rank is currently #3, and the Earnings ESP stands at -0.24%, suggesting a lower probability of beating estimates compared to stocks with positive signals.
📅 BDX reports Q2 fiscal 2026 earnings on May 7 before the market opens.
⚠️ Life Sciences faces pressure from US headwinds, China dynamics, and spin-off impacts.
🔄 Interventional and Medical segments expect solid growth driven by specific franchises.
📉 Revenue and EPS are projected to decline significantly year-over-year in Q2.
📉 Shares dropped 27.8% recently with a current Zacks Rank of #3 Hold.
📅 Becton, Dickinson and Company (BDX) is scheduled to report its second-quarter fiscal 2026 results on May 7 before the market opens.
💰 In the most recently reported quarter, BDX adjusted EPS of $2.91 exceeded the Zacks Consensus Estimate by 3.2%.
📉 Over the trailing four quarters, the company has consistently outperformed earnings estimates with an average surprise of 3.5%.
⚠️ BD Life Sciences is expected to face continued pressure in Q2 due to U.S. point-of-care headwinds and unfavorable market dynamics in China.
🔬 Biosciences within the Life Sciences segment encountered lower research funding and tough prior-year comparisons affecting licensing revenues.
🔄 The completion of the spin-off and combination with Waters Corporation has influenced reported performance for BD Life Sciences.
💡 BD Interventional is expected to maintain momentum with mid-single-digit growth driven by strong performance in Urology & Critical Care.
🩺 Growth in the Interventional segment was supported by double-digit expansion in the PureWick franchise and continued strength in Peripheral Intervention.
🚀 Product innovations, including the expansion of the Surgiphor wound irrigation portfolio and CE marking for the Revello vascular covered stent, are contributing to revenue growth.
💊 BD Medical is expected to carry forward solid Q1 performance driven by double-digit expansion in biologic drug delivery within BioPharma Systems.
🔌 Connected Care segment momentum is being driven by growth in pharmacy automation and advanced patient monitoring platforms like HemoSphere Alta.
🩸 Specimen Management growth is supported by ongoing demand for the BD Vacutainer portfolio to improve workflow efficiency.
📉 The Zacks Consensus Estimate for Q2 fiscal 2026 total revenue is pegged at $4.67 billion, implying an 11.5% decline year-over-year.
💸 EPS consensus estimates are currently set at $2.77, indicating a projected 17.3% decrease from the prior year.
📉 Over the past three months, BDX shares have declined by 27.8%, significantly underperforming the Medical - Dental Supplies sector and the S&P 500.
🏥 Key peers including The Cooper Companies, Henry Schein, and McKesson Corporation have outperformed BDX over the same timeframe.
⭐ BDX currently carries a Zacks Rank of #3 (Hold) and has an Earnings ESP of -0.24%, which may indicate a lower chance of beating estimates compared to higher-ranked stocks.
Bullish Signals
BDX beat Q earnings estimates by 3.2%.
Company outperformed consensus with average 3.5% surprise.
BDX stock dropped 27.8%, underperforming peers like McKesson (down 14.9%).
Zacks Rank #3 signals neutral or bearish potential compared to Strong Buy.
Earnings ESP of -0.24% suggests historical earnings surprise underperformance.
Q2 fiscal 2026 forecasts show 11.5% revenue and 17.3% EPS declines.
Diagnostic Solutions faces U.S. headwinds and unfavorable China market dynamics.
Bullish Signals
BDX delivered adjusted earnings per share of $2.91 in the last reported quarter, surpassing analyst estimates by 3.2%.
Over a trailing four-quarter period, the company has outperformed consensus estimates on all occasions with an average earnings surprise of 3.5%.
BD Interventional is expected to maintain momentum driven by mid-single-digit growth in the first quarter, including high single-digit expansion in Urology & Critical Care.
The PureWick franchise within BD Interventional achieved double-digit growth, supported by continued strength in Peripheral Intervention and oncology portfolios.
The Surgery business saw robust growth aided by strong performance in advanced tissue regeneration and infection prevention products.
Product innovations such as the expansion of the Surgiphor wound irrigation portfolio and CE marking for the Revello vascular covered stent in Europe are expected to drive early adoption and growth.
BD Interventional revenues are projected to increase to $1.36 billion, representing a 7.4% uptick from the year-ago quarter's reported figure.
BD Medical demonstrated broad-based growth across key platforms, including double-digit expansion in biologic drug delivery and high single-digit growth in advanced patient monitoring.
Risk Factors
BDX's stock has lost 27.8% over the past three months, significantly underperforming peers like McKesson Corporation (down 14.9%), Henry Schein (down 3.1%), and The Cooper Companies (down 21.5%).
The company carries a Zacks Rank #3 (Hold), which is neutral or potentially bearish compared to the Strong Buy or Buy ratings that indicate higher chances of beating earnings estimates.
Earnings ESP stands at -0.24%, indicating an expectation for the stock to underperform its historical earnings surprises prior to this quarter's report.
BD Life Sciences segment revenues are expected to remain under pressure due to headwinds in Diagnostic Solutions (U.S. point-of-care issues, unfavorable China market dynamics) and Biosciences (lower research funding, tough licensing comparisons).
Consensus estimates for second-quarter fiscal 2026 show a significant decline of 11.5% in total revenues and a 17.3% decrease in EPS compared to the prior-year quarter.
U.S. point-of-care headwinds and unfavorable market dynamics in China continue to weigh on the Diagnostic Solutions business within BD Life Sciences.
Market analysts anticipate a year-over-year decline in earnings for Becton Dickinson and Company (BDX) when it reports results for the quarter ended March 2026, with an earnings release scheduled for May 7. The consensus expectation is that quarterly earnings will be $2.77 per share, representing a 17.3% decrease compared to the same quarter last year, while revenues are projected to reach $4.67 billion, marking an 11.5% drop from the previous year. Over the past 30 days, the consensus earnings per share (EPS) estimate has been revised downward by 0.56%, reflecting a collective reassessment of initial predictions by covering analysts.
In evaluating the potential for a positive earnings surprise, the Zacks Earnings ESP model indicates a challenging outlook for BDX. The Most Accurate Estimate is currently lower than the Zacks Consensus Estimate at an Earnings ESP of -0.24%, suggesting recent bearishness among analysts regarding the company's earnings prospects. Although BDX holds a Zacks Rank of #3 (Hold), research shows that predictive power for beating estimates is strongest with positive ESP readings and strong buy or buy ranks; consequently, the combination of a negative ESP and a Hold rank makes it difficult to confidently predict that BDX will exceed the consensus EPS estimate. Historical data shows the company beat estimates in four out of the last four quarters reported, though prior quarter results show an actual surprise of +3.19% against an expectation of $2.82 per share when delivering $2.91 per share.
The article notes that while a miss may negatively impact the stock price, other factors such as management's discussion on business conditions during the earnings call will heavily influence investor sentiment and stock movement. To provide context, the report contrasts BDX with peer Dentsply Sirona Inc. (XRAY), which is also expected to report for the March 2026 quarter. XRAY has a projected EPS of $0.28 per share (a -34.9% year-over-year change) and revenues of $840.06 million (down 4.4%). Unlike BDX, XRAY shows a positive Earnings ESP of +1.98% combined with a Zacks Rank of #3, suggesting it is more likely to beat consensus estimates, although its historical beat rate over the last four quarters is two out of four. Investors are advised to consider both EPS surprises and qualitative catalysts when betting on these stocks ahead of their respective earnings releases.
💰 Revenue expected to drop 11.5% year-over-year to $4.67 billion.
📉 EPS forecast at $2.77, reflecting a 17.3% decline.
📅 Earnings report scheduled for release on May 7.
📊 Stock currently holds a Zacks Rank of #3 (Hold).
⚠️ Historical beats may not guarantee future stock movement.
📉 Analysts anticipate a year-over-year decline in Becton Dickinson's Q2 earnings with expected EPS of $2.77, down 17.3% from the prior year.
💰 Revenue is forecast to be $4.67 billion, representing an 11.5% decrease compared to the same quarter last year.
📅 The company is scheduled to release its earnings report for the quarter ended March 2026 on May 7.
🔄 Consensus EPS estimates have been revised downward by 0.56% over the past 30 days, reflecting analyst bearishness.
🤖 Becton Dickinson's Earnings ESP is -0.24% because its Most Accurate Estimate falls below the Zacks Consensus Estimate.
📊 The stock currently holds a Zacks Rank of #3 (Hold), which makes predicting an earnings beat difficult alongside the negative ESP.
📈 Historical performance shows Becton Dickinson has beaten consensus estimates four times in the last four reported quarters.
⚠️ A positive earnings beat or miss alone may not drive stock movement if other disappointing factors exist.
🔍 For context, peer Dentsply International (XRAY) carries a positive Earnings ESP of +1.98% and is expected to beat estimates.
🗓️ The Zacks Earnings Calendar is recommended for tracking upcoming earnings announcements across the medical-dental supplies industry.
Bullish Signals
The stock currently carries a Zacks Rank of #3 (Hold), which is associated with positive investment sentiment.
Historically, the company has beaten consensus EPS estimates in four out of the last four reported quarters.
In its most recent past quarter, the company delivered a positive earnings surprise of +3.19% on actual earnings of $2.91 per share versus expectations.
Management's discussion during the upcoming earnings call on May 7 could provide additional optimistic catalysts that drive the stock price higher despite lower consensus estimates.
Risk Factors
The market anticipates a year-over-year earnings decline of -17.3% with expected quarterly EPS of $2.77 per share.
Total revenues are projected to drop significantly by 11.5% to $4.67 billion for the quarter ended March 2026.
The consensus EPS estimate has been revised 0.56% lower over the last 30 days, indicating growing analyst pessimism.
Analysts have recently shifted to a more bearish stance as the Most Accurate Estimate is now lower than the Zacks Consensus Estimate.
The Earnings ESP reading stands at -0.24%, suggesting that analysts expect actual results to fall short of the consensus.
Becton Dickinson carries a Zacks Rank of #3 (Hold), which complicates predictions for an earnings beat given the negative ESP signal.
Historical data from the last quarter shows a surprise of +3.19%, but over the last four quarters, the company has only beaten estimates four times, creating uncertainty about future performance.
Becton Dickinson and Company (BDX) is scheduled to report second-quarter earnings for the period ended March 2026 on May 7, with market expectations predicting a year-over-year decline in both revenues and earnings per share. Analysts currently estimate quarterly earnings at $2.77 per share, representing a 17.3% decrease from the previous year, while projected revenues stand at $4.67 billion, down 11.5%. These consensus estimates have been revised downward by approximately 0.56% over the last 30 days, reflecting growing analyst caution regarding the company's near-term outlook.
The article utilizes the Zacks Earnings ESP model to assess the likelihood of an earnings surprise, noting that for Becton Dickinson, the Most Accurate Estimate is currently lower than the consensus average, resulting in a negative Earnings ESP of -0.24%. Despite the stock maintaining a Zacks Rank of #3 (Hold), which typically offers strong predictive power for positive surprises when combined with a positive ESP, the current combination suggests that Becton Dickinson is not a compelling candidate for beating earnings expectations based solely on this metric.
Historical data indicates that Becton Dickinson has beaten consensus EPS estimates four times over its last four reported quarters, with the most recent quarter showing a surprise of +3.19% when it produced earnings of $2.91 against an expectation of $2.82. However, the article clarifies that past performance does not guarantee future results and that stock price movements can be influenced by factors other than the binary beat or miss of earnings figures. The piece concludes by highlighting that while betting on companies expected to beat consensus increases odds of success, investors should also weigh other catalysts before trading the stock ahead of its May 7 release.
As an ancillary comparison, the text briefly mentions peer company Dentsply International (XRAY), which is expected to report earnings for March 2026 at $0.28 per share with an Earnings ESP of +1.98% despite a Zacks Rank of #3, suggesting different dynamics compared to Becton Dickinson.
📉 BDX faces projected declines with EPS at $2.77 and revenue down 11.5%.
🔮 Negative Earnings ESP suggests a difficult-to-predict outcome for the upcoming report.
👀 Investors should watch management discussions for clues on future sustainability.
📉 Market analysts expect Becton Dickinson (BDX) to report a year-over-year earnings decline when results are released on May 7.
💰 Quarterly earnings are projected at $2.77 per share, representing a significant -17.3% drop from the previous year.
📉 Revenue is forecasted to fall to $4.67 billion, which is an 11.5% decrease compared to the year-ago quarter.
📝 Analyst consensus estimates for BDX have been revised 0.56% lower over the last 30 days due to recent bearish reassessments.
🔮 The Zacks Earnings ESP model shows a -0.24% reading, indicating that the Most Accurate Estimate is lower than the Consensus Estimate.
📊 Becton Dickinson currently holds a Zacks Rank of #3, but the negative Earnings ESP makes an earnings beat difficult to predict.
📜 Historically, BDX has beaten consensus EPS estimates four times over the last four quarters, including a +3.19% surprise in the most recent quarter.
⚠️ Investors are cautioned that a stock may still move lower despite beating expectations due to other disappointing factors mentioned by management.
👀 Analysts advise monitoring the company's discussion of business conditions during the earnings call for future sustainability clues.
🦷 A peer comparison is made with Dentsply International (XRAY), which is expected to report earnings of $0.28 per share.
💸 Dentsply International projects revenues of $840.06 million with an 11.5% decline in revenue compared to the prior year.
📈 Dentsply shows a positive Earnings ESP of +1.98%, suggesting a higher probability of beating estimates than its BDX counterpart.
🏆 Zacks research indicates that a positive Earnings ESP combined with Strong Buy or Hold ranks predicts an earnings beat nearly 70% of the time.
❗️ A negative Earnings ESP reading, like BDX's -0.24%, is not considered a strong predictor of an earnings miss by itself.
📉 The consensus EPS estimate for Dentsply has been revised 3.9% lower recently, yet it retains a positive surprise prediction model reading.
Bullish Signals
Becton Dickinson (BDX) has beaten estimates in all four recent quarters.
Company recently delivered a +3.19% earnings surprise per share.
Becton Dickinson maintains Zacks Rank #3 with high predictive power.
Watch for May 7 release as beats could drive stock higher.
Risk Factors
BDX earnings decline -17.3% YoY forecasted.
Revenue contracted 11.5% to $4.67B estimate.
Analyst sentiment turned bearish recently.
Earnings ESP negative at -0.24%.
Zacks Rank #3 suggests hard prediction of positive surprise.
Bullish Signals
Becton Dickinson (BDX) demonstrated a strong historical track record of beating consensus estimates, having outperformed expectations in all four of the last reported quarters.
The company previously delivered an earnings surprise of +3.19% when it posted $2.91 per share compared to the expected $2.82 per share in the most recent quarter ended March 2026.
Despite current analyst revisions, Becton Dickinson maintains a Zacks Rank of #3 (Hold), which is associated with increased predictive power for earnings surprises when combined with positive Earnings ESP indicators.
Investors should monitor the upcoming earnings release scheduled for May 7, as results beating expectations could drive stock movement higher regardless of aggregate consensus estimates.
Risk Factors
Becton Dickinson (BDX) is expected to report a significant year-over-year earnings decline of -17.3%, with quarterly EPS forecasted at $2.77.
Revenue growth is also anticipated to contract substantially, with estimates pointing to an 11.5% year-over-year drop to $4.67 billion.
Analyst sentiment has turned bearish recently, as the Most Accurate Estimate fell below the Zacks Consensus Estimate, driving the Earnings ESP negative at -0.24%.
The negative Earnings ESP reading suggests there is no strong indicator that BDX will beat earnings expectations, despite a history of four beats in the last four quarters.
Analysts have collectively revised their consensus EPS estimate 0.56% lower over the past 30 days, reflecting worsening business condition assessments.
The combination of a negative Earnings ESP and a Zacks Rank of #3 (Hold) makes it difficult to predict a positive earnings surprise with confidence.
Wolf of Value rates Becton, Dickinson and Company (BDX) as a 'BUY' under $160/share, citing attractive fundamentals and a conservative valuation approach despite the company's recent spin-off of its high-margin bioscience segment. The analysis highlights that BDX retains core medical technology operations which maintain solid profitability and robust cash flow generation. The analyst views BDX's current price-to-earnings (P/E) ratio of 13x as undervalued, projecting a fair value target of $215/share by 2028E and estimating an annualized return above 15% at current prices.
Although the company meets key quality and safety criteria, the analyst notes that the spin-off has reduced diversification and margin potential, which warrants adopting a conservative 15x P/E multiple for valuation purposes rather than applying higher multiples typically seen in diversified medical technology firms. The author emphasizes an investment strategy focused on cheap, qualitative companies with appealing market share and solid economic moats within the healthcare and healthtech sectors. Wolf of Value, managed by a senior analyst and private portfolio manager with over 10 years of experience, provides this research alongside model portfolios and real-time chat access for its members.
The article includes standard financial disclosures stating that the author holds no stock or options in BDX and has no business relationships with the company. It explicitly clarifies that while the content is structured as a value-oriented investment idea, it is not financial advice, and investors are expected to perform their own due diligence. The analyst owns European/Scandinavian tickers for listed companies in those regions and Canadian tickers for Canadian stocks, acknowledging specific withholding tax risks associated with non-US investments. Seeking Alpha's disclosures reiterate that past performance does not guarantee future results and that the views expressed do not necessarily reflect those of the platform as a whole.
📉 BDX is a 'BUY' with a conservative target of under $160/share.
📊 Analysts view BDX's current P/E ratio of 13x as undervalued compared to its conservative potential.
🎯 A fair value target of $215/share is projected for the year 2028E based on value-oriented analysis.
🚀 Investors could expect an annualized return exceeding 15% at current price levels.
⚠️ The reduction in diversification warrants a conservative valuation approach, such as a 15x P/E multiple.
🏥 The investment thesis focuses on BDX's solid moat and appealing market share in the healthcare sector.
🔍 Wolf of Value covers healthcare and healthtech companies with a focus on cheap, qualitative investments.
💬 Members gain access to model portfolios, real-time updates, and direct analyst chat features.
⚡ The analyst has over 10 years of experience managing value-oriented portfolios in European and North American markets.
🛡️ Disclaimer states the author is not licensed to give financial advice and investors must do their own due diligence.
Bullish Signals
Becton, Dickinson and Company (BDX) is explicitly rated a 'BUY' with a recommended price under $160/share.
The company retains core medtech operations that demonstrate solid profitability and robust cash flow generation despite the bioscience segment spin-off.
Analyst models BDX as undervalued at its current 13x P/E ratio compared to a fair value target of $215/share by 2028E.
Investors are positioned for an annualized return above 15% based on current stock prices and valuation metrics.
BDX satisfies key quality and safety criteria, indicating strong operational reliability and market position.
Risk Factors
The spin-off of the high-margin bioscience segment has reduced BDX's diversification and margin potential.
Despite retaining core operations, the company's valuation is being capped at a conservative 15x P/E multiple instead of the 13x currently observed.
Investors must note that past performance is no guarantee of future results and the author explicitly states they are not licensed to give financial advice.
Becton Dickinson and Fraser (NYSE:BDX) has demonstrated recent progress in its interventional and home care segments through positive clinical data for two key products. The Liverty TIPS Stent Graft, designed to treat portal hypertension, is advancing toward European Union approval backed by pivotal clinical results expected at a major scientific meeting. Additionally, the company reported favorable outcomes for its PureWick Urine Collection System, which reinforces non-invasive management and patient comfort for urinary incontinence. These developments underscore the firm's focus on product innovation in liver disease care and aging-related home health solutions, expanding its addressable markets beyond traditional diagnostics and biologics delivery.
Financially, BDX shares are trading at $155.46, reflecting a 20.3% decline year to date and a 5.1% decline over the past month, though the stock has recorded a modest 1.7% return over the last year. Analyst forecasts project earnings growth of 9.96% annually with a reliable 2.7% dividend yield, suggesting potential value for investors seeking income combined with growth tied to new product uptake. The company continues to push a narrative centered on connected care and chronic disease management, with recent launches including the HemoSphere Stream Module, Pyxis Pro, and BD Incada aligning with trends toward procedure-centric and home-based medical solutions.
Despite these positives, investors are advised to monitor specific risks that could impact the investment thesis. Analysts have flagged concerns regarding debt levels not being well-covered by operating cash flow, which could limit balance sheet flexibility if cash generation does not keep pace with continued device launches and clinical programs. Furthermore, expanding into complex interventional therapies increases exposure to product-specific setbacks, including slower adoption rates, regulatory delays, or post-market safety findings. Regulatory complexity and operational risks associated with AI-powered medication management also add another dimension to the company's risk profile.
Looking ahead, key metrics for evaluating BDx include clinical and real-world evidence from the ARCH trial and the uptake of new products in European markets. For the Liverty TIPS Stent Graft, success will depend on clinician response once ARCH data is presented and whether CE Mark approval translates to meaningful use across EU liver centers. Success for the PureWick system hinges on prescription trends and home care adoption among older patients preferring to avoid institutional settings. Future earnings commentary regarding procedure volumes, recurring consumables, and software revenue will help determine if these strategic initiatives are successfully feeding into the broader company story against peers like Medtronic, Boston Scientific, Coloplast, Baxter, and ICU Medical.
📈 Becton Dickinson advances Liverty TIPS and PureWick toward EU approval with positive trial data.
📉 Stock down 5.1% monthly despite positive annual returns and 2.7% dividend yield.
⚠️ Analysts caution high debt limits flexibility while earnings forecast grows nearly 10% annually.
🎯 Strategic focus shifts to interventional therapies, connected care, and chronic disease management solutions.
📊 Upcoming earnings will clarify adoption rates for new devices and software revenue streams.
📈 Becton Dickinson advanced its Liverty TIPS Stent Graft for portal hypertension toward EU approval following positive pivotal clinical data presentation.
💧 The company confirmed positive results for the PureWick Urine Collection System, supporting non-invasive management of urinary incontinence.
🏥 These developments expand Becton Dickinson's reach in liver disease care and home-based solutions for aging populations.
📉 Stock price declined 5.1% over the past month to $155.46, despite a positive one-year return of 1.7%.
💼 New launches align with a strategic narrative focusing on higher acuity interventional therapies and connected chronic disease management.
⚠️ Analysts warn that the company's debt is not well covered by operating cash flow, potentially limiting balance sheet flexibility for future launches.
🛡️ Expanding into complex portfolios increases exposure to product-specific risks such as slower adoption or regulatory delays.
💰 Earnings are forecast to grow at 9.96% annually with a reliable dividend yield of 2.7%.
📉 The stock currently trades at a discount to certain fair value estimates while delivering new devices for chronic conditions.
🎯 For Liverty TIPS, investment focus will center on clinician response to ARCH trial data and CE Mark approval in the EU.
🏠 PureWick's home-based study results aim to address uptake among older patients wishing to avoid institutional care.
🖥️ Hospital adoption of HemoSphere Stream Module and Pyxis Pro will indicate acceptance of BD's connected care offerings versus competitors.
📊 Upcoming earnings calls will provide key commentary on procedure volumes, recurring consumables revenue, and software revenue tied to new launches.
🌐 The company is also rolling out products like the BD Incada suite in Europe, adding another angle to decentralized care trends.
Bullish Signals
Liverty TIPS Stent Graft advancing toward EU approval with pivotal data.
PureWick Urine Collection System shows positive clinical results for urinary incontinence.
Analysts forecast earnings to grow 9.96% annually as new products gain uptake.
Trading at discount to fair value estimates provides upside against targets.
Expansion into AI therapy aligns with connected care and chronic disease trends.
Risk Factors
Stock down 20.3% YTD despite positive clinical data.
Debt not well covered by operating cash flow.
AI and interventional expansion increases operational risks.
Larger portfolios expose company to product setbacks.
New launches face competition from major peers.
European rollout lacks confirmed revenue impact.
Future success depends on prescription trends.
Bullish Signals
Becton Dickinson advanced its Liverty TIPS Stent Graft for portal hypertension toward EU approval, supported by pivotal clinical data to be presented at a major scientific meeting.
The company reported positive clinical results for its PureWick Urine Collection System, reinforcing comfort and efficacy for non invasive management of urinary incontinence.
Analysts forecast earnings to grow 9.96% per year, indicating sustained revenue expansion from new product uptake.
Investors can rely on a consistent 2.7% dividend yield while waiting for continued device launches and clinical programs to mature.
The stock is described as trading at a discount to certain fair value estimates, offering potential upside against analyst targets.
Expansion into complex interventional therapies and AI powered medication management aligns with growing trends in connected care and chronic disease management.
Risk Factors
The stock has declined significantly year to date (20.3%) and over the past month (5.1%), despite recent positive clinical data and product advancements.
Analysts have flagged that BD's debt is not well covered by operating cash flow, which could limit balance sheet flexibility if cash generation does not keep pace with continued device launches and clinical programs.
Expanding into complex interventional therapies and AI-powered medication management increases execution and regulatory demands, amplifying concerns about operational risk and regulatory complexity.
Larger and more complex portfolios in interventional and connected care increase exposure to product-specific setbacks such as slower adoption, regulatory delays, or post-market safety findings.
The Liverty TIPS Stent Graft and Pyxis Pro/BD Incada launches face competition from peers like Medtronic, Boston Scientific, Baxter, and ICU Medical, which could limit market share gains if real-world outcomes do not align with trial data.
European rollout of the Pyxis Pro and BD Incada devices is mentioned without confirmed revenue impact, creating uncertainty about adoption rates and financial contribution in that region.
Future success depends heavily on prescription trends and home care uptake for PureWick and clinical acceptance of ARCH trial data for Liverty TIPS, introducing execution risk if clinician response is lukewarm.
Shares of Becton Dickinson & Co. (BDX) decreased by 1.04% on Thursday, closing at $155.46, marking a loss despite the broader market's strong performance. The S&P 500 Index rose 0.62% to close at 6,824.66, while the Dow Jones Industrial Average climbed 0.58% to reach 48,185.80 during an all-around favorable trading session.
Despite today's price decline, BDX stock continues to outperform its competitors in a positive trading environment. The company's current share price remains significantly below its recent peak; specifically, BDX is closing 17.02% below its 52-week high of $187.35, which was previously reached on February 24th.
The article notes that while BDX experienced a loss, the overall market strength contributed to a relatively favorable outcome for the stock. The provided data reflects intraday movements based on trades reported through Nasdaq and end-of-day data supplied by FACTSET, with real-time quotes reflecting U.S. trading hours.
📉 BDX shares fell 1.04% to $155.46 despite market gains.
📊 Stock underperformed broader indices but outpaced competitors in session.
📉 Price remains 17.02% below 52-week high of $187.35.
📉 Becton Dickinson & Co. (BDX) shares declined 1.04% to $155.46 on Thursday.
📊 The stock underperformed the broader market, with the S&P 500 rising 0.62% and the Dow Jones rising 0.58%.
📈 Despite the daily loss, BDX still outperformed its competitors during this trading session.
📉 The stock price remains 17.02% below its 52-week high of $187.35, set on February 24th.
💼 This market data is supported by partnerships with Dow Jones and FactSet for automated insights.
Risk Factors
Shares down 1.04%, underperforming as S&P 500 rose 0.62% and Dow climbed 0.58%.
Stock closed 17.02% below 52-week high of $187.35 reached Feb 24.
Risk Factors
Shares of Becton Dickinson & Co. (BDX) shed 1.04% to $155.46, underperforming the broader market as the S&P 500 rose 0.62% and the Dow Jones Industrial Average climbed 0.58%.
The stock closed 17.02% below its 52-week high of $187.35, which was reached on February 24th, indicating a significant pullback from peak valuations.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)